<page><tag>3</tag><title>QLT Prostate Cancer Treatment Wins FDA OK</title><text> TORONTO (Reuters) - QLT Inc. &amp;lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=QLT.TO target=/stocks/quickinfo/fullquote"&amp;gt;QLT.TO&amp;lt;/A&amp;gt; &amp;lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=QLTI.O target=/stocks/quickinfo/fullquote"&amp;gt;QLTI.O&amp;lt;/A&amp;gt; said on  Wednesday it won U.S. regulatory approval for the six-month  formulation of its prostate cancer treatment, Eligard.</text></page>